VarmX
VarmX is a biotech company focused on developing innovative approaches for the reversal of anticoagulation, specifically targeting FXa-DOACs and inherited coagulation disorders. Their mission is to revolutionize the treatment of severe bleeding through a fast, safe, and effective medicine, with their lead compound VMX-C001 designed to rapidly restore blood coagulation in patients taking Factor Xa inhibitors. The company aims to stop severe bleeding, eliminate bleeding risks during surgery, and improve patient outcomes with their novel therapies.
Industries
Nr. of Employees
small (1-50)
VarmX
Products
Modified recombinant human factor X therapeutic (lead clinical candidate)
A modified recombinant human coagulation factor X protein designed to be insensitive to inhibition by factor Xa direct oral anticoagulants and to restore coagulation in patients requiring reversal of FXa-DOAC anticoagulation.
Modified recombinant human factor X therapeutic (lead clinical candidate)
A modified recombinant human coagulation factor X protein designed to be insensitive to inhibition by factor Xa direct oral anticoagulants and to restore coagulation in patients requiring reversal of FXa-DOAC anticoagulation.
Services
Collaborative preclinical and translational research
Partnerships to conduct preclinical efficacy studies, coagulation assay development and translational biomarker assessments for anticoagulation-reversal therapeutic programs.
Clinical development services for first-in-human studies
Design and execution of early-phase clinical studies including randomized, placebo-controlled single-ascending-dose designs with integrated PK/PD, safety and immunogenicity assessments.
Scientific communication and investor engagement
Presentation of data at scientific conferences and engagement with investors and partnering networks to support program funding and strategic partnerships.
Collaborative preclinical and translational research
Partnerships to conduct preclinical efficacy studies, coagulation assay development and translational biomarker assessments for anticoagulation-reversal therapeutic programs.
Clinical development services for first-in-human studies
Design and execution of early-phase clinical studies including randomized, placebo-controlled single-ascending-dose designs with integrated PK/PD, safety and immunogenicity assessments.
Scientific communication and investor engagement
Presentation of data at scientific conferences and engagement with investors and partnering networks to support program funding and strategic partnerships.
Expertise Areas
- Anticoagulation reversal therapies
- Hemostasis and thrombosis research
- Clinical development (Phase 1 trials)
- Coagulation assay development and validation
Key Technologies
- Recombinant protein engineering
- Preclinical bleeding models (cynomolgus monkey liver injury)
- Diluted Russell viper venom time (dRVVT) assay
- Diluted prothrombin time (dPT) assay